Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.
Acetylsalicylic acid (ASA) and three structurally related benzoic acid derivatives, 2-acetylbenzoic acid (ABA), 3-methylphthalide (3-MP), and 3-hydroperoxy-3-methylphthalide (3-HMP), were tested for inhibitory effects on three human blood platelet cyclic nucleotide phosphodiesterase (PDE) activities. 3-MP caused a dose-dependent inhibition of the high and low affinity cyclic AMP PDE activities and the cyclic GMP PDE activity. 3-HMP had some inhibitory effects but only on the low affinity cyclic AMP PDE activity. ASA and ABA had no effects. This study shows that progressive structural changes in the ASA molecule can shift the pharmacological profile from a cyclooxygenase inhibitor (ASA) to an inactive compound (ABA) to a PDE inhibitor (3-MP) and back again to a cyclooxygenase inhibitor (3-HMP). It is proposed that the potent anti-inflammatory effects of 3-MP, which differ from those of ASA, are mediated through the inhibition of the cyclic nucleotide PDE system.
J J
JJ
Killackey
B A
BA
Killackey
R B
RB
Philp
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000097:blood; D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000097:blood; D001565:Benzoates / Q000494:pharmacology*; D019817:Benzoic Acid; D001792:Blood Platelets / Q000201:enzymology; D006801:Humans; D007700:Kinetics; D010795:Phthalic Acids / Q000494:pharmacology*; D010796:Phthalic Anhydrides / Q000494:pharmacology*; D013379:Substrate Specificity
D001565:Benzoates; D010795:Phthalic Acids; D010796:Phthalic Anhydrides; D019817:Benzoic Acid; C040698:3-hydroperoxy-3-methylphthalide; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D015056:1-Methyl-3-isobutylxanthine